Apoptosis-inducing effect of myxoma virus on human neuroglioma cell lines

Zhang,Qiu‑Sheng; Zhang,Meng; Huang,Xian‑Jian; Liu,Xiao‑Jia; Li,Wei‑Ping

doi:10.3892/etm.2017.4487

Apoptosis-inducing effect of myxoma virus on human neuroglioma cell lines

Authors:
- Qiu‑Sheng Zhang
- Meng Zhang
- Xian‑Jian Huang
- Xiao‑Jia Liu
- Wei‑Ping Li
View Affiliations

Affiliations: Department of Neurosurgery, Shenzhen Clinical College Affiliated to Anhui Medical University, Shenzhen, Guandong 518000, P.R. China, Department of Neurosurgery, Shenzhen 2nd People's Hospital, Shenzhen, Guangdong 508035, P.R. China
Published online on: May 22, 2017 https://doi.org/10.3892/etm.2017.4487
Pages: 344-348

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to further evaluate the role of myxoma virus (MYXV) as an oncolytic agent against experimental human gliomas in vitro, and analyze the effect of MYXV on malignant glioma cells at different incubation periods and infected at different multiplicities of infection. Neuroglioma cell lines U251 and A172 were cultured with various infective doses of myxoma virus at different time points (0‑3 days) and cellular survival rates were evaluated using an MTT assay. Cell viability and cell death rates were assessed using Annexin V/propidium iodide and applying flow cytometry. Furthermore, the expression levels of phosphorylated AKT (p‑AKT) in malignant gliomas were detected by western blot analysis to investigate the possible cell signaling targets in the pathway. MYXV exhibited a dose and time‑dependent cytotoxic effect on neuroglioma cells, and there was increased expression of p‑AKT in malignant gliomas. The present study confirms that MYXV induces oncolysis of malignant gliomas through regulating the activation of AKT. As such, MYXV is a potential therapeutic agent against human malignant gliomas.

View Figures

View References

1	Laws ER: Management of (malignant) intracranial gliomas. Practical Handbook of Neurosurgery. 549–558. 2009. View Article : Google Scholar
2	Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG and Forsyth P: Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol. 46:183–188. 1999. View Article : Google Scholar : PubMed/NCBI
3	Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW and Forsyth PA: Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 93:903–912. 2001. View Article : Google Scholar : PubMed/NCBI
4	Csatary LK, Gosztonyi G, Szeberenyi J, Fabian Z, Liszka V, Bodey B and Csatary CM: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol. 67:83–93. 2004. View Article : Google Scholar : PubMed/NCBI
5	Freeman AI, Gomori JM, Linetsky E, Zakay-Rones Z, Panet A, Libson E, Irving CS, Galun E and Siegal T: Phase I/II trial of intravenous OV001 oncolytic virus in resistant glioblastoma multiforme (GBM). J Clin Oncol. 22:15152004. View Article : Google Scholar
6	Stanford MM and McFadden G: Myxoma virus and oncolytic virotherapy: A new biologic weapon in the war against cancer. Expert Opin Biol Ther. 7:1415–1425. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kirn DH and Thorne SH: Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 9:64–71. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lun X, Yang W, Alain T, Shi ZQ, Muzik H, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL and Forsyth PA: Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 65:9982–9990. 2005. View Article : Google Scholar : PubMed/NCBI
9	Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL and Forsyth PA: Targeting human medulloblastoma: Oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 67:8818–8827. 2007. View Article : Google Scholar : PubMed/NCBI
10	Almansour NM, Pirogova E, Coloe PJ, Cosic I and Istivan TS: A bioactive peptide analogue for myxoma virus protein with a targeted cytotoxicity for human skin cancer in vitro. J Biomed Sci. 19:652012. View Article : Google Scholar : PubMed/NCBI
11	Coffey MC, Strong JE, Forsyth PA and Lee PW: Reovirus therapy of tumors with activated ras pathway. Science. 282:1332–1334. 1998. View Article : Google Scholar : PubMed/NCBI
12	Norman KL, Hirasawa K, Yang AD, Shields MA and Lee PW: Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA. 101:pp. 11099–11104. 2004; View Article : Google Scholar : PubMed/NCBI
13	Werden SJ and McFadden G: Pharmacological manipulation of the Akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells. J Virol. 84:3287–3302. 2010. View Article : Google Scholar : PubMed/NCBI
14	Correa RJ, Komar M, Tong JG, Sivapragasam M, Rahman MM, McFadden G, Dimattia GE and Shepherd TG: Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol Oncol. 125:441–450. 2012. View Article : Google Scholar : PubMed/NCBI
15	Smallwood SE, Rahman MM, Smith DW and McFadden G: Myxoma virus: Propagation, purification, quantification and storage. Curr Protoc Microbiol Chapter. 14:Unit: 14A. 12010.
16	Johnston JB, Barrett JW, Chang W, Chung CS, Zeng W, Masters J, Mann M, Wang F, Cao J and McFadden G: Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol. 77:5877–5888. 2003. View Article : Google Scholar : PubMed/NCBI
17	Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ and McFadden G: Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA. 103:pp. 4640–4645. 2006; View Article : Google Scholar : PubMed/NCBI
18	Hentschel SJ and Lang FF: Current surgical management of glioblastoma. Cancer J. 9:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
19	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
20	Thorne SH and Kirn DH: Future directions for the field of oncolytic virotherapy: A perspective on the use of vaccinia virus. Expert Opin Biol Ther. 4:1307–1321. 2004. View Article : Google Scholar : PubMed/NCBI
21	Shah AC, Benos D, Gillespie GY and Markert JM: Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol. 65:203–226. 2003. View Article : Google Scholar : PubMed/NCBI
22	Norman KL, Farassati F and Lee PW: Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev. 12:271–282. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hu CW, Yin GF, Wang XR, Ren BW, Zhang WG, Bai QL, Lv YM, Li WL and Zhao WQ: IL-24 induces apoptosis via upregulation of RNA-activated protein kinase and enhances temozolomide-induced apoptosis in glioma cells. Oncol Res. 22:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
24	Górski J, Mizak B and Chrobocińska M: Control of rabbit myxomatosis in poland. Rev Sci Tech. 13:869–879. 1994. View Article : Google Scholar : PubMed/NCBI
25	Rivers TM and Ward SM: Infectious myxomatosis of rabbits: Preparation of elementary bodies and studies of serologically active materials associated with the disease. J Exp Med. 66:1–14. 1937. View Article : Google Scholar : PubMed/NCBI
26	Barrett JW, Alston LR, Wang F, Stanford MM, Gilbert PA, Gao X, Jimenez J, Villeneuve D, Forsyth P and McFadden G: Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol. 13:549–560. 2007. View Article : Google Scholar : PubMed/NCBI